#Japan #Tokyo #Sky Labs #CART BP pro #Otsuka Pharmaceutical

Partnership Overview

Sky Labs Inc. has recently entered into a significant partnership with Otsuka Pharmaceutical Co., Ltd. aimed at bringing its ground-breaking blood pressure monitoring device, CART BP pro, to hospitals and clinics across Japan. This exclusive distribution agreement was officially announced on February 6, 2026, marking a pivotal moment in Sky Labs' aspirations for global expansion.

The collaboration follows a memorandum of understanding signed between the two companies in December 2024. Initially, Sky Labs explored opportunities for international expansion through its partner Otsuka Pharmaceutical Korea. This progression has led to formal discussions with the global headquarters of Otsuka, showcasing a successful story of open innovation that bridges a Korean startup with a major multinational's local affiliate in Japan.

Importance of the Device

CART BP pro is highly relevant in Japan, where approximately 43 million people suffer from hypertension, a condition that remains poorly controlled in nearly 29% of cases, with about 33% of patients unaware of their condition. The device’s technology has been clinically validated and is already adopted by over 1,700 medical institutions in South Korea, having gained National Health Insurance coverage.

In Japan, the growing incidence of abnormal blood pressure profiles and nocturnal hypertension has prompted a need for better monitoring solutions. This creates an opportunity for CART BP pro, which addresses the clinical need for 24-hour ambulatory blood pressure monitoring (ABPM), facilitating accurate diagnosis and optimal treatment strategies.

The CART BP pro not only offers a solution for constant monitoring but is also designed to be comfortable. Unlike traditional blood pressure monitors that use an inflatable cuff, the CART BP pro employs photoplethysmography (PPG) technology, allowing patients to easily measure their blood pressure without discomfort during daily activities or sleep. This advancement aids healthcare providers by delivering stable data essential for developing tailored treatment plans.

Technological Validation

Sky Labs' CEO, Jack Byunghwan Lee, underscores their commitment to global validation of their unique blood pressure monitoring technology, stating, “Beginning with our entry into the Japanese market, we will continue to validate our unique blood pressure monitoring technology globally.” The CART BP pro has already achieved medical device certification from the Korean Ministry of Food and Drug Safety and has surpassed 150,000 prescriptions since its national launch in 2023, illustrating its reliability and clinical efficacy.

Impact on Healthcare

By leveraging Otsuka's robust pharmaceutical presence and distribution capabilities in Japan, Sky Labs aims to enhance public health outcomes for hypertension management in the country. The potential impact of CART BP pro is substantial, as it provides a means to elevate healthcare standards through its advanced monitoring capabilities. This partnership symbolizes a strategic alignment of expertise in addressing a growing public health concern while showcasing innovative health technology.

In conclusion, this collaboration sets a promising trajectory for Sky Labs as it embarks on its first international venture, with Otsuka Pharmaceutical supporting its ambitions and paving a pathway towards improved health monitoring in Japan.

For more information about Sky Labs, visit Sky Labs.

For further details on Otsuka Pharmaceutical, please refer to Otsuka.